| Oct 2027 to Jan 2028Quarter disclosed | MK-8690 | MRK | Topline readout | Rheumatoid Arthritis | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | MK-7262 | MRK | Primary completion | Lipoprotein(a) | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | MK-8527 | MRK | Primary completion | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | MK-8690 | MRK | Primary completion | Rheumatoid Arthritis | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | MK-8690 | MRK | Primary completion | Colitis Ulcerative; Ulcerative Colitis | Scheduled | ClinicalTrials.gov |
| Nov 2027 to Feb 2028Quarter disclosed | opevesostat (MK-5684) | MRK | Topline readout | Malignant Neoplasm | Scheduled | ClinicalTrials.gov |
| Nov 2027 to Feb 2028Quarter disclosed | Lipfendra (enlicitide decanoate) | MRK | Topline readout | Hyperlipidemia; Hypercholesterolemia | Scheduled | ClinicalTrials.gov |
| November 2027Month disclosed | opevesostat (MK-5684) | MRK | Primary completion | Malignant Neoplasm | Scheduled | ClinicalTrials.gov |
| November 2027Month disclosed | Lipfendra (enlicitide decanoate) | MRK | Primary completion | Hyperlipidemia; Hypercholesterolemia | Scheduled | ClinicalTrials.gov |
| Dec 2027 to Mar 2028Quarter disclosed | zilovertamab vedotin (MK-2140) | MRK | Topline readout | Lymphoma, Large B-Cell, Diffuse | Scheduled | ClinicalTrials.gov |
| Dec 2027 to Mar 2028Quarter disclosed | V503 | MRK | Topline readout | Papillomavirus Infections | Scheduled | ClinicalTrials.gov |
| Dec 2027 to Mar 2028Quarter disclosed | alimatravir (MK-8527) | MRK | Topline readout | HIV | Scheduled | ClinicalTrials.gov |
| December 2027Month disclosed | alimatravir (MK-8527) | MRK | Primary completion | HIV | Scheduled | ClinicalTrials.gov |
| December 2027Month disclosed | zilovertamab vedotin (MK-2140) | MRK | Primary completion | Lymphoma, Large B-Cell, Diffuse | Scheduled | ClinicalTrials.gov |
| December 2027Month disclosed | V503 | MRK | Primary completion | Papillomavirus Infections | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2028Quarter disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Topline readout | Endometrial Cancer | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2028Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Non-small Cell Lung Cancer (NSCLC) | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2028Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Renal Cell Carcinoma | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2028Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| January 2028Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Renal Cell Carcinoma | Scheduled | ClinicalTrials.gov |
| January 2028Month disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Primary completion | Endometrial Cancer | Scheduled | ClinicalTrials.gov |
| January 2028Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| January 2028Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Non-small Cell Lung Cancer (NSCLC) | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | V503 | MRK | Topline readout | Papillomavirus Infections | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | pembrolizumab (+) berahyaluronidase alfa (MK-3475A) | MRK | Topline readout | Squamous Cell Carcinoma | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | V503 | MRK | Primary completion | Papillomavirus Infections | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | pembrolizumab (+) berahyaluronidase alfa (MK-3475A) | MRK | Primary completion | Squamous Cell Carcinoma | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | opevesostat (MK-5684) | MRK | Topline readout | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms | Scheduled | ClinicalTrials.gov |
| May 2028Month disclosed | opevesostat (MK-5684) | MRK | Primary completion | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Topline readout | Cervical Cancer | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | ifinatamab deruxtecan (MK-2400) | MRK | Topline readout | Prostate Cancer; Prostatic Neoplasms | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | WINREVAIR (sotatercept) | MRK | Topline readout | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Primary completion | Cervical Cancer | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | WINREVAIR (sotatercept) | MRK | Primary completion | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | ifinatamab deruxtecan (MK-2400) | MRK | Primary completion | Prostate Cancer; Prostatic Neoplasms | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2028Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | High-risk Non-muscle Invasive Bladder Cancer | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2028Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Malignant Melanoma | Scheduled | ClinicalTrials.gov |
| July 2028Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Malignant Melanoma | Scheduled | ClinicalTrials.gov |
| July 2028Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | High-risk Non-muscle Invasive Bladder Cancer | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2028Quarter disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Topline readout | Non-small Cell Lung Cancer (NSCLC) | Scheduled | ClinicalTrials.gov |
| August 2028Month disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Primary completion | Non-small Cell Lung Cancer (NSCLC) | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Colorectal Neoplasms | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | WINREVAIR (sotatercept) | MRK | Topline readout | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Malignant Neoplam; Advanced Solid Tumors | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Colorectal Neoplasms | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | WINREVAIR (sotatercept) | MRK | Primary completion | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Malignant Neoplam; Advanced Solid Tumors | Scheduled | ClinicalTrials.gov |
| Oct 2028 to Jan 2029Quarter disclosed | iv tulisokibart (PRA023) | MRK | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Oct 2028 to Jan 2029Quarter disclosed | Lipfendra (enlicitide decanoate) | MRK | Topline readout | Hypercholesterolemia | Scheduled | ClinicalTrials.gov |
| Oct 2028 to Jan 2029Quarter disclosed | tiespectus (MK-8748) | MRK | Topline readout | Diabetic Retinopathy; Macular Edema | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | Lipfendra (enlicitide decanoate) | MRK | Primary completion | Hypercholesterolemia | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | iv tulisokibart (PRA023) | MRK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | tiespectus (MK-8748) | MRK | Primary completion | Diabetic Retinopathy; Macular Edema | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | Pifeltro (doravirine) | MRK | Topline readout | Human Immunodeficiency Virus (HIV) Infection | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | opevesostat (MK-5684) | MRK | Topline readout | Prostate Cancer Metastatic | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | pembrolizumab (+) berahyaluronidase alfa (MK-3475A) | MRK | Topline readout | — | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | tiespectus (MK-8748) | MRK | Topline readout | Diabetic Retinopathy; Macular Edema | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | pembrolizumab (+) berahyaluronidase alfa (MK-3475A) | MRK | Primary completion | — | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | Pifeltro (doravirine) | MRK | Primary completion | Human Immunodeficiency Virus (HIV) Infection | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | opevesostat (MK-5684) | MRK | Primary completion | Prostate Cancer Metastatic | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | tiespectus (MK-8748) | MRK | Primary completion | Diabetic Retinopathy; Macular Edema | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | WINREVAIR (sotatercept) | MRK | Topline readout | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | WINREVAIR (sotatercept) | MRK | Primary completion | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | nemtabrutinib (ARQ-531) | MRK | Topline readout | Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Non-small Cell Lung Cancer; NSCLC | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | nemtabrutinib (ARQ-531) | MRK | Primary completion | Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Non-small Cell Lung Cancer; NSCLC | Scheduled | ClinicalTrials.gov |
| Feb to May 2029Quarter disclosed | 9vhpv vaccine (V503) | MRK | Topline readout | Genital Warts | Scheduled | ClinicalTrials.gov |
| February 2029Month disclosed | isl (MK-8591) | MRK | Primary completion | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Scheduled | ClinicalTrials.gov |
| Feb to May 2029Quarter disclosed | isl (MK-8591) | MRK | Topline readout | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Scheduled | ClinicalTrials.gov |
| February 2029Month disclosed | 9vhpv vaccine (V503) | MRK | Primary completion | Genital Warts | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | calderasib (MK-1084) | MRK | Topline readout | Colon Adenocarcinoma; Rectal Adenocarcinoma | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | calderasib (MK-1084) | MRK | Primary completion | Colon Adenocarcinoma; Rectal Adenocarcinoma | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | zilovertamab vedotin (MK-2140) | MRK | Topline readout | Lymphoma, Large B-Cell, Diffuse (DLBCL) | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Topline readout | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | MK-2214 | MRK | Topline readout | Early Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | Ohtuvayre (ensifentrine) | MRK | Topline readout | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | zilovertamab vedotin (MK-2140) | MRK | Primary completion | Lymphoma, Large B-Cell, Diffuse (DLBCL) | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Primary completion | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | Ohtuvayre (ensifentrine) | MRK | Primary completion | Pulmonary Disease, Chronic Obstructive | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | MK-2214 | MRK | Primary completion | Early Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | MK-8591A | MRK | Topline readout | HIV-1 Infection | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | 9vhpv vaccine (V503) | MRK | Topline readout | Papillomavirus Infections | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | zilovertamab vedotin (MK-2140) | MRK | Topline readout | Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | WINREVAIR (sotatercept) | MRK | Topline readout | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | zilovertamab vedotin (MK-2140) | MRK | Primary completion | Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | WINREVAIR (sotatercept) | MRK | Primary completion | Pulmonary Arterial Hypertension | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | 9vhpv vaccine (V503) | MRK | Primary completion | Papillomavirus Infections | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | MK-8591A | MRK | Primary completion | HIV-1 Infection | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2029Quarter disclosed | tulisokibart (PRA023) | MRK | Topline readout | Noninfectious Intermediate, Posterior, or Panuveitis | Scheduled | ClinicalTrials.gov |
| June 2029Month disclosed | tulisokibart (PRA023) | MRK | Primary completion | Noninfectious Intermediate, Posterior, or Panuveitis | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | zilovertamab vedotin (MK-2140) | MRK | Topline readout | Diffuse Large B-Cell Lymphoma | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Squamous Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Topline readout | Bladder Cancer | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | zilovertamab vedotin (MK-2140) | MRK | Primary completion | Diffuse Large B-Cell Lymphoma | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Squamous Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | sacituzumab tirumotecan (MK-2870) | MRK | Primary completion | Bladder Cancer | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | 9vhpv vaccine (V503) | MRK | Topline readout | Papillomavirus Infections | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | Verquvo (vericiguat) | MRK | Topline readout | Heart Failure; Left Ventricular Systolic Dysfunction | Scheduled | ClinicalTrials.gov |